Abstract:Stroke and late-onset Alzheimer's disease (AD) are risk factors for each other; the comorbidity of these brain disorders in aging individuals represents a significant challenge in basic research and clinical practice. The similarities and differences between stroke and AD in terms of pathogenesis and pathophysiology, however, have rarely been comparably reviewed. Here, we discuss the research background and recent progresses that are important and informative for the comorbidity of stroke and late-onset AD and related dementia (ADRD). Glutamatergic NMDA receptor (NMDAR) activity and NMDAR-mediated Ca2+ influx are essential for neuronal function and cell survival. An ischemic insult, however, can cause rapid increases in glutamate concentration and excessive activation of NMDARs, leading to swift Ca2+ overload in neuronal cells and acute excitotoxicity within hours and days. On the other hand, mild upregulation of NMDAR activity, commonly seen in AD animal models and patients, is not immediately cytotoxic. Sustained NMDAR hyperactivity and Ca2+ dysregulation lasting from months to years, nevertheless, can be pathogenic for slowly evolving events, i.e. degenerative excitotoxicity, in the development of AD/ADRD. Specifically, Ca2+ influx mediated by extrasynaptic NMDARs (eNMDARs) and a downstream pathway mediated by transient receptor potential cation channel subfamily M member (TRPM) are primarily responsible for excitotoxicity. On the other hand, the NMDAR subunit GluN3A plays a "gatekeeper" role in NMDAR activity and a neuroprotective role against both acute and chronic excitotoxicity. Thus, ischemic stroke and AD share an NMDAR- and Ca2+-mediated pathogenic mechanism that provides a common receptor target for preventive and possibly disease-modifying therapies. Memantine (MEM) preferentially blocks eNMDARs and was approved by the Federal Drug Administration (FDA) for symptomatic treatment of moderate-to-severe AD with variable efficacy. According to the pathogenic role of eNMDARs, it is conceivable that MEM and other eNMDAR antagonists should be administered much earlier, preferably during the presymptomatic phases of AD/ADRD. This anti-AD treatment could simultaneously serve as a preconditioning strategy against stroke that attacks ≥ 50% of AD patients. Future research on the regulation of NMDARs, enduring control of eNMDARs, Ca2+ homeostasis, and downstream events will provide a promising opportunity to understand and treat the comorbidity of AD/ADRD and stroke.

Glutamate excitotoxicity: Potential therapeutic target for ischemic stroke

Network-Based Approach to Identify Potential Targets and Drugs That Promote Neuroprotection and Neurorepair in Acute Ischemic Stroke

Excitatory Synaptic Transmission in Ischemic Stroke: A New Outlet for Classical Neuroprotective Strategies

Glutamate Antagonists in Therapy of Stroke

Excitotoxic Storms of Ischemic Stroke: A Non-neuronal Perspective

Synaptic and Extrasynaptic Glutamate Signaling in Ischemic Stroke

Disrupted Ionic Homeostasis in Ischemic Stroke and New Therapeutic Targets.

Potential Neuroprotective Treatment of Stroke: Targeting Excitotoxicity, Oxidative Stress, and Inflammation

Glutamate as a co-agonist for acid-sensing ion channels to aggravate ischemic brain damage

Signaling Pathways in Brain Ischemia: Mechanisms and Therapeutic Implications.

Glutamate acts on acid-sensing ion channels to worsen ischaemic brain injury

Glutamate-releasing BEST1 channel is a new target for neuroprotection against ischemic stroke with wide time window

Targeting harmful effects of non-excitatory amino acids as an alternative therapeutic strategy to reduce ischemic damage

Molecular targets in cerebral ischemia for developing novel therapeutics

Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer's disease

Acute and chronic excitotoxicity in ischemic stroke and late-onset Alzheimer's disease

Glutamate Receptor-Independent Calcium Toxicity Pathways in Acute Ischemic Brain Injury

Molecular and cellular mechanisms of excitotoxic neuronal death

Glutamate receptors and white matter stroke

Receptors, Channel Proteins, and Enzymes Involved in Microglia-mediated Neuroinflammation and Treatments by Targeting Microglia in Ischemic Stroke

Blood glutamate scavenging as a novel glutamate-based therapeutic approach for post-stroke depression